PCMK
ABBV icon

Paragon Capital Management (Kansas)’s AbbVie ABBV Stock Holding History

Paragon Capital Management (Kansas)’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$286K Buy
1,316
+429
+48% +$95.2K 0.14% 54
2025
Q4 		$203K Buy
+887
New +$202K 0.1% 59
2025
Q1 		– Sell
-1,260
Closed -$224K – 51
2024
Q4 		$224K Buy
1,260
+211
+20% +$38.8K 0.12% 51
2024
Q3 		$207K Buy
+1,049
New +$196K 0.11% 60

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Paragon Capital Management (Kansas)'s ABBV Position: Q1 2026 in Review

Paragon Capital Management (Kansas) increased its AbbVie (ABBV) stake by 48% in Q1 2026, buying an estimated $95.2K and bringing the position to 1,316 shares worth $286K. The position accounts for 0.14% of the portfolio, ranked #54.

Paragon Capital Management (Kansas) first reported a position in ABBV in Q3 2024 and has held it in 4 quarters since. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Paragon Capital Management (Kansas) held 1,316 shares of AbbVie worth $286K as of Q1 2026.
  • Paragon Capital Management (Kansas) bought 429 AbbVie shares in Q1 2026, an estimated $95.2K.
  • AbbVie made up 0.14% of Paragon Capital Management (Kansas)'s portfolio in Q1 2026, its #54 holding.
  • Paragon Capital Management (Kansas) first reported a position in AbbVie in Q3 2024 and has held it in 4 quarters since.
  • 4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Paragon Capital Management (Kansas)'s 13F filing for Q1 2026, filed 15 May 2026.